CG
ITCI

Cutler Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Cutler Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$2K Buy
+600
New +$41.2K ﹤0.01% 1928
2022
Q4 		– Sell
-3,000
Closed -$1K – 5403
2022
Q3 		$1K Sell
3,000
-1,700
-36% -$88.8K ﹤0.01% 4755
2022
Q2 		$23K Sell
4,700
-5,200
-53% -$295K ﹤0.01% 2571
2022
Q1 		$59K Buy
9,900
+6,100
+161% +$317K ﹤0.01% 2121
2021
Q4 		$39K Buy
3,800
+2,800
+280% +$118K ﹤0.01% 2604
2021
Q3 		$8K Sell
1,000
-9,100
-90% -$316K ﹤0.01% 4160
2021
Q2 		$22K Buy
10,100
+9,000
+818% +$333K ﹤0.01% 3251
2021
Q1 		$8K Sell
1,100
-2,000
-65% -$69.4K ﹤0.01% 4040
2020
Q4 		$34K Sell
3,100
-1,900
-38% -$49.9K ﹤0.01% 2286
2020
Q3 		$25K Sell
5,000
-4,000
-44% -$91.3K ﹤0.01% 2294
2020
Q2 		$46K Buy
9,000
+7,700
+592% +$156K ﹤0.01% 1808
2020
Q1 		$6K Sell
1,300
-39,600
-97% -$860K ﹤0.01% 3029
2019
Q4 		$378K Buy
40,900
+28,300
+225% +$340K 0.02% 548
2019
Q3 		$4K Buy
12,600
+5,500
+77% +$52.7K ﹤0.01% 3229
2019
Q2 		$18K Buy
7,100
+5,000
+238% +$64.1K ﹤0.01% 2301
2019
Q1 		$1K Sell
2,100
-19,100
-90% -$244K ﹤0.01% 3851
2018
Q4 		$5K Buy
21,200
+9,600
+83% +$155K ﹤0.01% 2959
2018
Q3 		$50K Buy
11,600
+600
+5% +$12.5K ﹤0.01% 1617
2018
Q2 		$30K Buy
11,000
+1,800
+20% +$36.5K ﹤0.01% 1935
2018
Q1 		$48K Sell
9,200
-3,200
-26% -$62.3K ﹤0.01% 1697
2017
Q4 		$23K Sell
12,400
-41,100
-77% -$635K ﹤0.01% 2460
2017
Q3 		$100K Buy
53,500
+34,000
+174% +$499K ﹤0.01% 1678
2017
Q2 		$38K Sell
19,500
-92,700
-83% -$1.07M ﹤0.01% 2778
2017
Q1 		$150K Buy
112,200
+103,000
+1,120% +$1.49M 0.01% 1404
2016
Q4 		$19K Sell
9,200
-149,400
-94% -$2.11M ﹤0.01% 3527
2016
Q3 		$29K Buy
158,600
+99,400
+168% +$4.02M ﹤0.01% 3059
2016
Q2 		$134K Buy
59,200
+34,500
+140% +$1.24M 0.01% 1443
2016
Q1 		$14K Buy
24,700
+10,300
+72% +$343K ﹤0.01% 3707
2015
Q4 		$139K Buy
+14,400
New +$726K 0.01% 1487

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cutler Group's ITCI Position: Q1 2024 in Review

Cutler Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 300 shares — an estimated $20.6K sold.

Cutler Group first reported a position in ITCI in Q4 2015 and held it in 27 quarters. The position peaked at $576K in Q3 2017. 345 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • Cutler Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 300 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $20.6K.
  • Cutler Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 27 quarters.
  • Cutler Group's Intra-Cellular Therapies Inc. position peaked at $576K in Q3 2017.
  • 345 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.